Silence Therapeutics ophthalmic news
Silence will consolidate its corporate activities to a more centralized location through the closure of its U.S. operations next quarter. As part of the restructuring, CEO Phillip Haworth will depart after the company identifies a successor. Silence said the board decided to close the U.S. operations due to operational difficulties and increased operating costs created by the "geographical diversity" of the company. The U.S. operation was responsible for business development, legal IP and general corporate management.
Silence is partnered with Quark Pharmaceuticals Inc. (Fremont, Calif.) and Pfizer Inc. (NYSE:PFE, New York, N.Y.) for PF-655 ( PF-04523655), which is in Phase II testing for diabetic macular edema (DME) and wet age-related macular degeneration (AMD). PF-655 is a short interfering RNA that inhibits the expression of DNA-damage-inducible transcript 4 ( DDIT4; RTP801). ...